ArticleLeukemia2009
Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.
Article in Leukemia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Nucleic acid aptamers in orthopedic diseases: promising therapeutic agents for bone disorders.Bone research · 2025Review
- Myeloma Bone Disease: A Comprehensive Review.International journal of molecular sciences · 2021Review
- The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment.Frontiers in oncology · 2021Article
- Multiple Myeloma and Bone: The Fatal Interaction.Cold Spring Harbor perspectives in medicine · 2018Review
- Deficient invariant natural killer T cells had impaired regulation on osteoclastogenesis in myeloma bone disease.Journal of cellular and molecular medicine · 2018Article
- LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens.Frontiers in immunology · 2018Article
- Myeloma and Bone Disease.Current osteoporosis reports · 2017Review
- Bone Regeneration Induced by Bone Porcine Block with Bone Marrow Stromal Stem Cells in a Minipig Model of Mandibular "Critical Size" Defect.Stem cells international · 2017Article
- Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells.Frontiers in endocrinology · 2016Review
- LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem Cells.PloS one · 2016Article
- Human myeloma cell lines induce osteoblast downregulation of CD99 which is involved in osteoblast formation and activity.Journal of immunology research · 2015Article
- Bone-immune cell crosstalk: bone diseases.Journal of immunology research · 2015Review
- LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.Oncotarget · 2014Article
- Osteoclastogenic potential of peripheral blood mononuclear cells in cleidocranial dysplasia.International journal of medical sciences · 2014Article
- Bone disease in multiple myeloma: pathophysiology and management.Cancer growth and metastasis · 2014Review
- Article
- The Interplay between the bone and the immune system.Clinical & developmental immunology · 2013Review
- Cellular mechanisms of multiple myeloma bone disease.Clinical & developmental immunology · 2013Review
- Myeloma cells suppress osteoblasts through sclerostin secretion.Blood cancer journal · 2011Article
- Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.Drugs · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Decoy receptor 3 (DcR3), a member of the tumor necrosis factor (TNF) receptor superfamily, is known to be involved in cell survival and osteoclast (OC) formation. In this study, we show that malignant plasma cells and T lymphocytes from multiple myeloma (MM) bone disease patients, as well as Karpas 909, a human myeloma cell line, directly produce DcR3. By interacting with FasL, this molecule could inhibit OC apoptosis. In fact, the use of a neutralizing anti-DcR3 antibody induces a reduction of cell viability with a consequent increase of apoptotic cell number, the activation of caspase-8 and -3, and DNA fragmentation. Furthermore, we show that DcR3 supports OC formation in samples from MM patients through the upregulation of RANKL and TNFalpha by T lymphocytes and only TNFalpha by CD14+ cells. In conclusion, our data provide the first evidence of the expression of DcR3 in MM, and the involvement of this molecule in supporting the survival and formation of OCs from MM bone disease patients. The production of DcR3 by T lymphocytes confers these cells a role in the pathogenesis of bone disease associated with MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.